Babesiosis — Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report — 2023 To 2033
Babesiosis is an infection of parasitic nature instigated by protozoa belonging to the genus Babesia. The species of Babesia have been categorized into four distinct clades. Babesia microti, classified as a Clade 1 organism, is the most prevalent and comprehensively described species. The primary mode of acquiring Babesiosis is through tick bites carrying the protozoa. Given that the parasite infects erythrocytes (red blood cells), the infection can also be contracted through blood transfusion, thereby affecting individuals not exposed to endemic areas. Babesia predominantly infects red blood cells, often appearing oval or pear-shaped. The ring form and peripheral location in the red blood cell can lead to misinterpretation of the smear for Plasmodium falciparum. However, unlike Plasmodium, hemolysis is rare in Babesiosis. The increased aggregation and rigidity of the red blood cells often result in acute respiratory distress and noncardiogenic pulmonary edema. Fragmentation of red blood cells can also lead to capillary blockage in various organs. The spleen, responsible for trapping damaged red cells, can become enlarged. Patients lacking a spleen tend to experience a more severe disease course. Asymptomatic Babesia infection may persist subclinically for months to years in otherwise healthy individuals, particularly those under 40. Symptomatic Babesiosis typically commences after a 1- to 2-week incubation period with nonspecific symptoms, including myalgia, headache, fever, chills, fatigue, malaise, and arthralgia. In healthy individuals, symptoms usually resolve after a week. In others, hepatosplenomegaly may occur with mild neutropenia, mild to moderately severe hemolytic anemia, jaundice, and thrombocytopenia. Noncardiac pulmonary edema can develop in severe disease. Asymptomatic patients usually do not require treatment, but therapy is indicated for patients with persistent high fever, rapidly increasing parasitemia, and falling hematocrit. The combination of atovaquone and azithromycin administered for 7 to 10 days has fewer adverse effects. It is as effective as traditional therapy with quinine plus clindamycin in patients with mild to moderate Babesiosis. The adult dosage is atovaquone 750 mg orally every 12 hours and azithromycin 500 to 1000 mg on the first day, followed by a daily dose of 250 to 1000 mg. In children weighing over 5 kg, the dosage is atovaquone 20 mg/kg orally twice a day plus azithromycin 10 mg/kg once, then 5 mg/kg daily for 7 to 10 days. Quinine 650 mg orally three times a day plus clindamycin 600 mg orally three times a day or 300 to 600 mg IV four times a day for 7 to 10 days can also be used. The pediatric dosage is quinine 10 mg/kg orally three times a day plus clindamycin 7 to 14 mg/kg three times daily. Quinine plus clindamycin is considered the standard of care for severely ill patients. Recipients of quinine must be monitored closely for adverse effects. In patients suffering from severe illness with high parasitemia (more than 10% of erythrocytes), exchange transfusion has been employed as a treatment method. The future health condition of Babesiosis patients is largely dependent on the nature of their symptoms. A majority of patients exhibit no symptoms and generally have a favorable prognosis. Some may experience an infection similar to the flu, which typically results in a positive outcome. However, patients with severe forms of the disease may face a lengthy recovery period marked by multiorgan dysfunction and, in some cases, death. This is particularly common in patients who do not have a spleen. Symptoms of Babesiosis can persist for 6–8 weeks, while patients without symptoms may go undiagnosed for several years. It is recommended that all patients who test positive for the disease three months after initial treatment undergo another round of treatment, regardless of whether they have experienced seizures. Approximately one-fifth of patients with Babesiosis may be co-infected with Lyme disease. These patients tend to have a more prolonged course.
Thelansis’s “Babesiosis Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report — 2023 To 2033” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Babesiosis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Babesiosis across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Babesiosis Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
